Melanoma, skin, Phase I-II

A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors

Volunteers
Health Professionals

What is the purpose of this trial?

A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Mario Sznol

mario.sznol@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Mario Sznol, MD
Professor of Medicine (Medical Oncology); Clinical Research Leader, Melanoma Program; Co-Leader, Cancer Immunology, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Sub-Investigators

Last Updated
12/21/2023
Study HIC
#2000033918